Otsuka, Lundbeck gain FDA nod for longer-acting version of schizophrenia drug Abilify

Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck.

On Thursday, the FDA signed off on Abilify Asimtufii, an extended-release, injectable suspension administered every two months. The drug is for treating adults with schizophrenia and for maintenance in adults with bipolar I disorder.